Equities

Notable Labs Ltd

NTBL:NAQ

Notable Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4491
  • Today's Change-0.029 / -6.05%
  • Shares traded191.58k
  • 1 Year change+103.17%
  • Beta0.9819
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 20-Sep-24
Select bar for recommendation details.
Recommendations20-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Notable Labs Ltd share price to rise to 9.00 in the next year from the last price of 0.4491.
High1,904.0%9.00
Med1,904.0%9.00
Low1,904.0%9.00

Earnings history & estimates in USD

On Aug 14, 2024, Notable Labs Ltd reported 2nd quarter 2024 losses of -0.55 per share.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-227.19%
Notable Labs Ltd reported annual 2023 losses of -3.41 per share on Apr 11, 2024.
Average growth rate+24.95%
More ▼

Revenue history & estimates in USD

Vascular Biogenics Ltd. had 2nd quarter 2024 revenues of 2.00k. The one analyst following the company did not expect it to generate revenues.
Average growth rate-100.00%
Vascular Biogenics Ltd. had revenues for the full year 2023 of 310.00k. Last year the company did not report any revenues.
Average growth rate-4.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.